losartan (Q410074)

114798-26-4 (English)

18 November 2016

chemical formula

C₂₂H₂₃ClN₆O

1 reference

114798-26-4 (English)

18 November 2016

canonical SMILES

CCCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)CO)Cl

1 reference

114798-26-4 (English)

https://www.whocc.no/atc_ddd_index/?code=C09CA01

18 November 2016

defined daily dose

50 milligram

route of administration

oral administration

1 reference

reference URL

1 reference

14 February 2018

World Health Organisation international non-proprietary name

losartan (English)

1 reference

losartan (English)

medical condition treated

3 October 2016

congestive heart failure

1 reference

13 December 2016

arterial hypertension

2 references

13 December 2016

Drug Indications Extracted from FAERS

significant drug interaction

2 October 2018

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

trimethoprim

1 reference

A reference set of clinically relevant adverse drug-drug interactions

triamterene

1 reference

A reference set of clinically relevant adverse drug-drug interactions

amiloride

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eplerenone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

spironolactone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

eplerenone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

spironolactone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

nabumetone

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

naproxen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

celecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

Diclofenac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

piroxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

meloxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-fenoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(+-)-flurbiprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

ibuprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

indomethacin

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-ketoprofen

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

(RS)-etodolac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

sulindac

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

parecoxib

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

tenoxicam

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

1 reference

A reference set of clinically relevant adverse drug-drug interactions

physically interacts with

angiotensin II receptor type 1

subject has role

antagonist

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

590

https://nctr-crs.fda.gov/fdalabel/ui/spl-summaries/criteria/343802

17 August 2016

legal status (medicine)

boxed warning

1 reference

reference URL

Australian pregnancy category D

FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links. (English)

pregnancy category

1 reference

imported from Wikimedia project

English Wikipedia

US pregnancy category D

1 reference

imported from Wikimedia project

English Wikipedia

LiverTox likelihood score

LiverTox toxicity likelihood category C

1 reference

8 April 2021

https://www.ncbi.nlm.nih.gov/books/n/livertox/Losartan

last update

13 January 2017

subject has role

angiotensin II receptor antagonist

1 reference

15 March 2018

1 reference

MeSH descriptor ID

D019808

15 March 2018

antihypertensive drug

1 reference

National Library of Spain ID

15 March 2018

0 references

0 references

0 references

Losartan

0 references

Identifiers

XX548580

0 references

InChI

InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)

1 reference

114798-26-4 (English)

18 November 2016

2 references

114798-26-4 (English)

18 November 2016

ChEBI release 2020-09-01

CAS Registry Number

114798-26-4

2 references

losartan (English)

18 November 2016

https://commonchemistry.cas.org/detail?cas_rn=114798-26-4

9 April 2021

1 reference

Losartan (English)

18 November 2016

2 references

114798-26-4 (English)

18 November 2016

Reaxys registry number

4770867

1 reference

losartan (English)

3 October 2016

mapping relation type

2 references

LOSARTAN (English)

18 November 2016

International Chemical Identifier

InChI

InChI=1S/C22H23ClN6O/c1-2-3-8-20-24-21(23)19(14-30)29(20)13-15-9-11-16(12-10-15)17-6-4-5-7-18(17)22-25-27-28-26-22/h4-7,9-12,30H,2-3,8,13-14H2,1H3,(H,25,26,27,28)

1 reference

LOSARTAN (English)

18 November 2016

2 references

inferred from InChIKey

SCHEMBL4222

2 references

based on heuristic

inferred from InChIKey

MSBNK-Athens_Univ-AU228001

1 reference

MassBank accession ID

0 references

0 references

0 references

0 references

0 references

MSBNK-Athens_Univ-AU228002

0 references

MSBNK-Athens_Univ-AU228003

0 references

MSBNK-Athens_Univ-AU228004

0 references

MSBNK-Athens_Univ-AU228005

0 references

MSBNK-Athens_Univ-AU228006

0 references

MSBNK-Athens_Univ-AU228010

0 references

MSBNK-Athens_Univ-AU228011

0 references

MSBNK-Athens_Univ-AU228012

0 references

MSBNK-Athens_Univ-AU228057

0 references

MSBNK-Athens_Univ-AU228058

0 references

MSBNK-Athens_Univ-AU228059

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

0 references

MSBNK-Waters-WA001418

0 references

MSBNK-Waters-WA001419

0 references

MSBNK-Waters-WA001420

0 references

MSBNK-Waters-WA001421

0 references

MSBNK-Waters-WA001422

0 references

MSBNK-Waters-WA001423

0 references

SPLASH

splash10-0a4i-0191000000-8ff1b5a21f6ef4a462cd

0 references

splash10-0a4i-0590000000-9841ff7f881c3e9c11b9

0 references

splash10-0a59-0960000000-a24e287a018dae01dd0d

0 references

splash10-0a5c-0930000000-ff3e675bd445225bf04e

0 references

splash10-0pxu-0920000000-9adf4aef59fc1545fea6

0 references

splash10-0v00-1900000000-3591888cf5831cbe3d11

0 references

splash10-0wmi-2900000000-ab9304c8cebc201d0178

0 references

splash10-0j70-5900000000-efa87b7770206ac0ff3e

0 references

splash10-00di-0000900000-657db16bb4bfe9184114

0 references

splash10-056r-0900000000-43bb8508cd1dbc71bcee

0 references

splash10-004i-0900000000-55368087829d113fdb7b

0 references

splash10-004i-0900000000-af470646c547613f82a0

0 references

splash10-004i-0900000000-746dcf7a43a3f8839c1d

0 references

splash10-004i-0900000000-0bee80f7ccbc4b68eee0

0 references

splash10-004i-0900000000-d845ae166a10faff242a

0 references

splash10-004i-2900000000-d39a309c02e1aaa956b0

0 references

splash10-004i-7900000000-d27d10ab008deb157e7a

0 references

splash10-0a4i-0491300000-f4b08850a154cfc2117c

0 references

splash10-00fr-0900700000-fef78a7f52d4aa515bb4

0 references

splash10-0a4i-0591300000-32a922edf20b3eb76950

0 references

splash10-00fr-0900600000-c62f0db44e17f79e0c70

0 references

splash10-0a4i-0391000000-d94cab952f9d339878eb

0 references

HSDB ID

7043

1 reference

Hazardous Substances Data Bank

28 October 2019

Losartan (English)

10 May 2021

2 references

Mapping file of InChIStrings, InChIKeys and DTXSIDs for the EPA CompTox Dashboard

DSSTOX compound identifier

0 references

0 references

0 references

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.555

27 December 2018

ECHA Substance Infocard ID

[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol (English)

quotation

CAS no.: 114798-26-4 (English)

100.110.555

1 reference

ECHA Substance Infocard database

ECHA Substance Infocard ID

100.110.555

27 December 2018

[2-butyl-4-chloro-1-({4-[2-(2H-1,2,3,4-tetrazol-5-yl)phenyl]phenyl}methyl)-1H-imidazol-5-yl]methanol (English)

quotation

CAS no.: 114798-26-4 (English)

1 reference

Guide to Pharmacology Ligand ID

Losartan (English)

publication date

17 November 2015

590

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

Guide to Pharmacology Ligand ID

590

reason for deprecated rank

losartan (English)

18 November 2016

applies to other chemical entity

1 reference

IUPHAR/BPS Guide to PHARMACOLOGY

5 February 2021

Losartan

1 reference

D02.455.426.559.389.185.475

14 March 2018

0 references

0 references

0 references

1 reference

losartan (English)

18 November 2016

1 reference

Human Metabolome Database ID

HMDB0014816

2 references

based on heuristic

inferred from InChIKey

2 references

losartan (English)

18 November 2016

MedlinePlus drug identifier

a695008

0 references

PatientsLikeMe treatment ID

0 references

1 reference

losartan (English)

18 November 2016

0 references

1 reference

1 reference

losartan (English)

3 October 2016

1 reference

Immune Epitope Database and Analysis Resource

losartan (English)

3 October 2016

1 reference

1 March 2022

0 references

0 references

electronic Essential Medicines List medicine ID

0 references

1 reference

28 October 2013

Microsoft Academic ID

0 references

0 references

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

1 reference

26 January 2022

https://docs.openalex.org/download-snapshot/snapshot-data-format

0 references

1 reference

imported from Wikimedia project

German Wikipedia

UK Parliament thesaurus ID

453279

subject named as

Losartan

0 references

UMLS CUI

C0126174

1 reference